Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMDAMBW)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Amperozide; 75558-90-6; Amperozidum [INN-Latin]; Amperozida [INN-Spanish]; UNII-0M2W3TAG39; FG 5606; 0M2W3TAG39; CHEMBL1079935; 4-(4,4-Bis(p-fluorophenyl)butyl)-N-ethyl-1-piperazinecarboxamide; 4-(4,4-Bis(4-fluorphenyl)butyl)-N-ethyl-1-piperazinecarboxamid; Amperozidum; Amperozida; 4-[4,4-bis(4-fluorophenyl)butyl]-n-ethylpiperazine-1-carboxamide; 1-Piperazinecarboxamide, 4-(4,4-bis(p-fluorophenyl)butyl)-N-ethyl-; Amperozide [INN:BAN]; Amperozide [BAN:INN]; 4-(4,4-Bis(4-fluorophenyl)butyl)-N-ethylpiperazine-1-carboxamide
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
